NCT00397722 is a Phase 2 clinical trial of GW876008 in Social Phobia, sponsored by GlaxoSmithKline.

Who is sponsoring NCT00397722?

NCT00397722 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT00397722?

Interventions in NCT00397722: GW876008, paroxetine.

What condition does NCT00397722 study?

NCT00397722 studies Social Phobia.

Is NCT00397722 still recruiting?

NCT00397722 is currently completed. Last updated 11 July 2017.

Last reviewed 2017-07-11 · How we verify

NCT00397722

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment Of Patients With Social Anxiety Disorder

Completed Phase 2 Last updated 11 July 2017

What this trial tests

Phase 2 trial testing GW876008 in Social Phobia in 299 participants. Completed in 5 September 2007.

Timeline

9 November 2006

Primary endpoint
5 September 2007

5 September 2007

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Primary purpose	treatment
Enrollment	299
Start date	9 November 2006
Primary completion	5 September 2007
Estimated completion	5 September 2007
Sites	33 locations across South Africa, Finland, Sweden, Germany, Norway, Canada, United States

Drugs / interventions tested

GW876008 — full drug profile →
paroxetine — full drug profile →

Conditions studied

Social Phobia — all drugs for Social Phobia →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 18 to 64, any sex, with Social Phobia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

GW876008 is a drug which may change mans reaction to stress, by decreasing the fear, physical and behavior symptoms that people with SocAD experience in social situations.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options.
Garakani A, Murrough JW, Freire RC, Thom RP, et al · · 2020 · cited 213× · PMID 33424664 · DOI 10.3389/fpsyt.2020.595584
Progress in corticotropin-releasing factor-1 antagonist development.
Zorrilla EP, Koob GF. · · 2010 · cited 131× · PMID 20206287 · DOI 10.1016/j.drudis.2010.02.011
Sex differences in corticotropin-releasing factor receptor-1 action within the dorsal raphe nucleus in stress responsivity.
Howerton AR, Roland AV, Fluharty JM, Marshall A, et al · · 2014 · cited 64× · PMID 24289884 · DOI 10.1016/j.biopsych.2013.10.013
Pharmacotherapy for social anxiety disorder (SAnD).
Williams T, Hattingh CJ, Kariuki CM, Tromp SA, et al · · 2017 · cited 37× · PMID 29048739 · DOI 10.1002/14651858.cd001206.pub3
Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology: Clinical practice guideline for social anxiety disorder (2021).
Asakura S, Yoshinaga N, Yamada H, Fujii Y, et al · · 2023 · cited 8× · PMID 37624975 · DOI 10.1002/npr2.12365
Antidepressants for social anxiety disorder: A systematic review and meta-analysis.
Mitsui N, Fujii Y, Asakura S, Imai H, et al · · 2022 · cited 6× · PMID 35848723 · DOI 10.1002/npr2.12275

Verify or expand the search:

Other trials of GW876008

Trials testing the same drug.

NCT00508911 — A Study To Evaluate The Effect Of GW876008 On The Pharmacokinetics Of Oral Contraceptive Pills · Phase 1 · terminated
NCT00385099 — Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome · Phase 2 · completed
NCT00421707 — Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome · Phase 2 · completed

Other recruiting trials for Social Phobia

Currently open trials in the same condition.

NCT06564402 — Augmentation of Exposure Using Positive Mental Rehearsal in Individuals With Increased Social Anxiety · NA · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00397722 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 11 July 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00397722.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing